Conference Reports for NATAP
15th International Workshop on
of HIV and Hepatitis Therapy
May 19- 21, 2014, Washington, DC
Idenix IDX437/IDX719 Development Program
Idenix Announces Promising Clinical Data and Continued Progress in Nucleotide Prodrug Development Programs for the Treatment of Hepatitis C
Favorable Preclinical Profile of IDX21437, a Novel Uridine Nucleotide Prodrug, for Use in a Direct-Acting Antiviral (DAA) Regimen for HCV
IDX719, HCV NS5A Inhibitor, Demonstrates Pan-Genotypic Activity after Three Days of Monotherapy in Genotype 1, 2, 3 or 4 HCV-Infected Subjects......
Idenix has 2 nucleotides being studied separately but they could be studied in combination.
Here are select slides from yesterday's Idenix investor conference call: